27.62
+5.58%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Supernus Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Supernus Pharmaceuticals is based in Rockville, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SUPN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.24bn and net income of $210.0m. At that date it held total assets of $1.20bn and shareholders' equity of −$98.0m.
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.
Headquartered in the U.S. in Richmond, Virginia, Indivior and its portfolio of products is available primarily in the U.S. with additional products available in Canada, Australia, France, and Germany.
Our business was initially developed and managed as a separate division of Reckitt Benckiser Group PLC (“RB” and, together with its subsidiaries, the “RB Group”), a public limited company incorporated under the laws of England and Wales. Indivior PLC was incorporated on September 26, 2014, for the purpose of acquiring the specialty pharmaceutical business unit from RB (the “Demerger”). Following the Demerger, which was effective on December 23, 2014, Indivior PLC operated as a standalone business.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Dec 2010
- Employees
- 778
- Website
- supernus.com ↗
- Head office
- 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Charles NewhallIndependent Chairman of the Board$399,688
- Mr. Jack KhattarPresident, Chief Executive Officer, Secretary, Director, since 2005$12.6m
- Mr. Timothy DecChief Financial Officer, Senior Vice President$2.3m
- Mr. Frank MottolaChief Operating Officer, Chief Technology Officer$1.3m
- Dr. Padmanabh BhattSenior Vice President - Intellectual Property, Chief Scientific Officer$1.3m
- Dr. Jonathan RubinSenior Vice President, Chief Medical Officer - Research and Development$1.5m
- Dr. Carrolee BarlowIndependent Director$368,688
- Dr. Georges GemayelIndependent Director$381,188
- Mr. Frederick HudsonIndependent Director$377,688
- Ms. Bethany SensenigIndependent Director$355,188
- Mr. Peter VozzoInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 26
- Environment
- 29
- Social
- 28
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Supernus Pharmaceuticals Inc possesses a robust product portfolio consisting of several innovative and FDA-approved drugs. The company's diverse range of products helps it maintain a competitive edge in the pharmaceutical industry.
- With years of experience operating in the pharmaceutical market, Supernus Pharmaceuticals Inc has established a strong market presence. Its reputation and brand recognition contribute to its ability to attract loyal customers and secure partnerships.
Weaknesses
- Despite its success in the domestic market, Supernus Pharmaceuticals Inc has limited global reach compared to some of its competitors. Expanding into international markets presents an opportunity for the company to further grow its business.
- Supernus Pharmaceuticals Inc relies heavily on a few key customers for a significant portion of its revenue. This dependency exposes the company to potential risks if any of these customers reduce or terminate their business relationships.
Opportunities
- The pharmaceutical industry is seeing favorable regulatory reforms, which create opportunities for Supernus Pharmaceuticals Inc to expedite the drug approval process and bring new products to market more efficiently.
- The increasing demand for specialty medications presents a growth opportunity for Supernus Pharmaceuticals Inc. By developing innovative drugs that target specific diseases or conditions, the company can tap into this growing market and expand its customer base.
Threats
- Supernus Pharmaceuticals Inc operates in a highly competitive industry characterized by the presence of numerous established players. Competitors may introduce similar or superior products, potentially impacting the company's market share and profitability.
- Pricing pressure and reimbursement challenges pose a threat to Supernus Pharmaceuticals Inc. The company must navigate the complex pricing and reimbursement landscape to ensure adequate compensation for its products while remaining cost-effective for patients and healthcare providers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.